222 related articles for article (PubMed ID: 15768345)
1. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
Litwin AH; Soloway I; Gourevitch MN
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
[TBL] [Abstract][Full Text] [Related]
2. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
3. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV.
Kresina TF; Bruce RD; Cargill VA; Cheever LW
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S83-8. PubMed ID: 16265621
[TBL] [Abstract][Full Text] [Related]
4. Treating hepatitis C virus infection in active substance users.
Sylvestre DL
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S321-4. PubMed ID: 15768341
[TBL] [Abstract][Full Text] [Related]
5. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
6. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
7. [Prevention and treatment of hepatitis C in illicit drug users].
Sakoman S
Acta Med Croatica; 2009 Dec; 63(5):437-42. PubMed ID: 20198904
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Hallinan R; Byrne A; Amin J; Dore GJ
J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
Backmund M; Reimer J; Meyer K; Gerlach JT; Zachoval R
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S330-5. PubMed ID: 15768343
[TBL] [Abstract][Full Text] [Related]
10. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection.
Dore GJ; Thomas DL
Semin Liver Dis; 2005 Feb; 25(1):18-32. PubMed ID: 15731995
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
12. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.
Sylvestre DL; Litwin AH; Clements BJ; Gourevitch MN
J Subst Abuse Treat; 2005 Oct; 29(3):159-65. PubMed ID: 16183464
[TBL] [Abstract][Full Text] [Related]
13. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.
Zeiler I; Langlands T; Murray JM; Ritter A
Drug Alcohol Depend; 2010 Aug; 110(3):228-33. PubMed ID: 20430537
[TBL] [Abstract][Full Text] [Related]
14. Integrating HCV services for drug users: a model to improve engagement and outcomes.
Sylvestre DL; Zweben JE
Int J Drug Policy; 2007 Oct; 18(5):406-10. PubMed ID: 17854729
[TBL] [Abstract][Full Text] [Related]
15. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment.
Sulkowski MS; Thomas DL
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S263-9. PubMed ID: 15768333
[TBL] [Abstract][Full Text] [Related]
17. Treatment for hepatitis C virus infection among current injection drug users in Australia.
Matthews G; Kronborg IJ; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S325-9. PubMed ID: 15768342
[TBL] [Abstract][Full Text] [Related]
18. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
Strauss SM; Astone JM; Jarlais DD; Hagan H
Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
[TBL] [Abstract][Full Text] [Related]
19. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection.
Hagan H; Strauss SM; Astone JM; Des Jarlais DC
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S297-303. PubMed ID: 15768338
[TBL] [Abstract][Full Text] [Related]
20. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
